SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (866)5/7/1998 12:19:00 PM
From: LLAH  Respond to of 1202
 
CardioGenesis ATLANTIC TMR Study- Randomized:

Primary Study Endpoints: CCS Angina Scale and
Exercise Tolerance

Secondary Endpoints: Quality of Life,
Perfusion (Stress Thallium) and
Ventricular Function (Echocardiography)

Study nearly complete with over 180 patients enrolled.
Expected PMA submission to FDA: 12/98-2/99
Anticipated FDA approval: mid 1999